A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Excluded: EGFR mutation

Participants must not have any known driver mutations with available targeted therapy (including but not limited to EGFR mutations...)

Excluded: ALK translocation

Participants must not have any known driver mutations with available targeted therapy (including but not limited to...ALK translocations...)

Excluded: ROS1 translocation

Participants must not have any known driver mutations with available targeted therapy (including but not limited to...ROS-1 translocations...)

Excluded: BRAF V600E

Participants must not have any known driver mutations with available targeted therapy (including but not limited to...known BRAFV600E...)

Excluded: RET activating mutation

participants with a known activating RET mutations

Excluded: NTRK1 fusion gene alteration

participants with a known...NTRK fusion gene alterations

Excluded: NTRK2 fusion gene alteration

participants with a known...NTRK fusion gene alterations

Excluded: NTRK3 fusion gene alteration

participants with a known...NTRK fusion gene alterations

Cannot have received: anti-PD-1 therapy

Participants must not have any prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.

Cannot have received: anti-PD-L1 therapy

Participants must not have any prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.

Cannot have received: anti-PD-L2 therapy

Participants must not have any prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.

Cannot have received: anti-CTLA-4 therapy

Participants must not have any prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.

Cannot have received: EGFR tyrosine kinase inhibitor

Participants must have no prior systemic anti-cancer treatment (including EGFR, ALK, ROS-1, BRAF, RET, and NTRK inhibitors) given as primary therapy for advanced or metastatic disease.

Cannot have received: ALK inhibitor

Participants must have no prior systemic anti-cancer treatment (including EGFR, ALK, ROS-1, BRAF, RET, and NTRK inhibitors) given as primary therapy for advanced or metastatic disease.

Cannot have received: ROS1 inhibitor

Participants must have no prior systemic anti-cancer treatment (including EGFR, ALK, ROS-1, BRAF, RET, and NTRK inhibitors) given as primary therapy for advanced or metastatic disease.

Cannot have received: BRAF inhibitor

Participants must have no prior systemic anti-cancer treatment (including EGFR, ALK, ROS-1, BRAF, RET, and NTRK inhibitors) given as primary therapy for advanced or metastatic disease.

Cannot have received: RET inhibitor

Participants must have no prior systemic anti-cancer treatment (including EGFR, ALK, ROS-1, BRAF, RET, and NTRK inhibitors) given as primary therapy for advanced or metastatic disease.

Cannot have received: NTRK inhibitor

Participants must have no prior systemic anti-cancer treatment (including EGFR, ALK, ROS-1, BRAF, RET, and NTRK inhibitors) given as primary therapy for advanced or metastatic disease.